Is compounded tirzepatide still legal to buy online in 2026? FDA’s dated statements

Is compounded tirzepatide still legal to buy online in 2026?

FDA has not published a single yes or no; its dated records say the tirzepatide injection shortage was resolved on December 19, 2024 (after an October 2, 2024 decision was sent back for reevaluation), and the grace periods FDA announced for compounders ended on March 5, 2025 for state-licensed pharmacies (503A) and March 19, 2025 for outsourcing facilities (503B). On April 1, 2026 FDA stated that tirzepatide is on neither the 503B bulks list nor its drug shortage list, and on April 30, 2026 it proposed not adding it to the 503B bulks list.

This page lists what FDA has published, with dates. It is not legal advice and does not say whether any company’s product is lawful.

FDA’s statements describe conditions under which compounding can qualify for exemptions in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. For how the two kinds of compounder differ, see 503A pharmacies and 503B outsourcing facilities.

FDA’s statements, by date

FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date. Each statement was re-checked against its source page on Nov 15, 2026.

Current status in FDA data (Nov 15, 2026)

FDA drug shortage list
No tirzepatide injection listed as a current shortage
503B bulks list proposal
No final determination published in the Federal Register docket FDA-2018-N-3240 as of this date
FDA warning letters naming compounded tirzepatide
95
Telehealth letters naming tirzepatide issued after the 503B grace period ended
87
Recall reports naming tirzepatide
28

Telehealth letters naming tirzepatide since Mar 19, 2025

False or misleading claims / misbranded51
Unapproved or misbranded drugs sold online36

Common questions

Can telehealth companies still sell compounded tirzepatide after the shortage ended?

FDA’s records set conditions rather than a yes or no: compounding under section 503A needs an individual prescription and may not regularly copy an approved drug, and outsourcing facilities may compound from bulk tirzepatide only if it is on the 503B bulks list or the shortage list, which FDA said on April 1, 2026 it is not. Since Mar 19, 2025, FDA has issued 87 warning letters to telehealth companies naming tirzepatide, most in the group “False or misleading claims / misbranded” (51).

Is tirzepatide on FDA’s drug shortage list?

No tirzepatide injection is listed as a current shortage in FDA’s data as of Nov 15, 2026.

What is the 503B bulks list?

It is FDA’s list of bulk drug substances outsourcing facilities may use in compounding because FDA found a clinical need. On April 30, 2026 FDA proposed not to include semaglutide, tirzepatide and liraglutide; the comment period was extended to July 30, 2026.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.